Testosterone recovery post-ADT is influenced by treatment duration, baseline testosterone levels, and patient age. Younger patients and those with higher baseline testosterone levels recover more ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

Men receiving treatment for prostate cancer often face challenges that extend well beyond the disease itself. A new study led ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

The testosterone threshold should be less than 10 ng/dL rather than less than 50 ng/dL for gauging advanced prostate cancer prognosis in patients on ADT. Examining sustained testosterone suppression ...

Patients who received ADT for 3 months or 9 months had worse overall survival than those treated for 36 months. For men with prostate cancer treated with definitive radiotherapy, the benefit derived ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.